Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Doxorubicin plays an integral role in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) but can be associated with significant toxicity. Treatment guidelines of British Columbia (BC) Cancer recommend the substitution of etoposide for doxorubicin in standard-dose R-CHOP (rituximab,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Moccia, Alden A., Schaff, Kimberly, Freeman, Ciara, Hoskins, Paul J., Klasa, Richard J., Savage, Kerry J., Shenkier, Tamara N., Gascoyne, Randy D., Connors, Joseph M., Sehn, Laurie H.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2021
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948286/
https://ncbi.nlm.nih.gov/pubmed/33683338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002982
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky